SCYNEXIS Inc (NASDAQ:SCYX) Director David C. Hastings bought 11,834 shares of SCYNEXIS stock in a transaction dated Thursday, March 8th. The shares were acquired at an average cost of $1.69 per share, for a total transaction of $19,999.46. Following the completion of the purchase, the director now directly owns 31,834 shares of the company’s stock, valued at approximately $53,799.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
SCYNEXIS Inc (SCYX) traded up $0.03 on Monday, hitting $1.46. The stock had a trading volume of 78,686 shares, compared to its average volume of 315,403. The company has a debt-to-equity ratio of 0.43, a quick ratio of 7.30 and a current ratio of 7.30. SCYNEXIS Inc has a 52-week low of $1.35 and a 52-week high of $3.24.
Several research firms have recently issued reports on SCYX. Zacks Investment Research cut SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. ValuEngine raised SCYNEXIS from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $7.75.
TRADEMARK VIOLATION NOTICE: “SCYNEXIS Inc (SCYX) Director Acquires $19,999.46 in Stock” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://sportsperspectives.com/2018/03/12/scynexis-inc-scyx-director-acquires-19999-46-in-stock.html.
SCYNEXIS Company Profile
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.